Schedule a COVID vaccine or booster appointment:
Log in to myPennMedicine or call us 8am to 5pm, Monday through Friday, at 267-758-4902.
Sees patients age 18 and up
English and Spanish
Sees patients age 18 and up
English and Spanish
Recognized by America's Top Doctors, 2008, 2010, 2011 - 2018
Recognized by Best Doctors in America 2003 - 2018
Recognized in Philadelphia magazine's annual Top Docs issues, 2002, 2008, and 2010 - 2021
Perelman Center for Advanced Medicine
West Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
The Patient Satisfaction Rating is an average of all responses to the care provider related question shown above from our internal platform, PMX Feedback. Responses are measured on a scale of 1 to 5 with 5 being the best score. Scores reflect either the most recent 12 months of surveys or the most recent 30 surveys overall. Data is updated monthly and comments remain on the profile for 12 months.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Patients that are treated in outpatient or hospital environments may receive different surveys.
New Drug Development for Urologic CancerCancer Survivorship
Lauritsen J, Sauvé N, Tryakin A, Jiang DM, Huddart R, Heng DYC, Terbuch A, Winquist E, Chovanec M, Hentrich M, Fankhauser CD, Shamash J, Del Muro XG, Vaughn D, Heidenreich A, Sternberg CN, Sweeney C, Necchi A, Bokemeyer C, Bandak M, Jandari A, Collette L, Gillessen S, Beyer J, Daugaard G.: Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
British Journal of Cancer 129 (11): 1759-1765,2023.
Maxwell R, Chang Y, Paul C, Vaughn DJ, Christodouleas JP: Cancer control, toxicity, and second malignancy risks of proton radiation therapy doe stage I-IIB testicular seminoma Advances in Radiation Oncology 8 (5): 101259,2023.
Pyle LC, Kim J, Bradfield J, Damrauer SM, D'Andrea K, Einhorn LH, Godse R, Hakonarson H, Kanetsky PA, Kember RL, Jacobs LA, Maxwell KN, Rader DJ, Vaughn DJ, Weathers B, Wubbenhorst B, Regeneron Genetics Center Research Team, Cancer Genomics Research Laboratory, Greene MH, Nathanson KL, Stewart DR: Germline exome sequencing for men with testicular germ cell tumor reveals coding defects in chromosomal segregation and protein-targeting genes European Urology 26 : S0302-2838,2023.
Sanchez VA, Shuey MM, Dinh PC Jr, Monahan PO, Fosså SD, Sesso HD, Dolan ME, Einhorn LH, Vaughn DJ, Martin NE, Feldman DR, Kroenke K, Fung C, Frisina RD, Travis LB.: Patient-reported functional impairment due to hearing loss and tinnitus after cisplatin-based chemotherapy.
Journal of Clinical Oncology 41 (12): 2211-2226,2023.
Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH.: Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals of Oncology 34 (3): 289-299,2023.
Shahbazi M, Zhang X, Dinh PC, Sanchez VA, Trendowski MR, Shuey MM, Nguyen T; Regeneron Genetics Center, Feldman DR, Vaughn DJ, Fung C, Kollmannsberger C, Martin NE, Einhorn LH, Cox NJ, Frisina RD, Travis LB, Dolan ME: Comprehensive association analysis of speech recognition thresholds after cisplatin-based chemotherapy in survivors of adult-onset cancer Cancer Medicine 12 (3): 2999-3012,2023.
Dinh PC, Monahan PO, Fosså SD, Sesso HD, Feldman DR, Dolan ME, Nevel K, Kincaid J, Vaughn DJ, Martin NE, Sanchez VA, Einhorn LH, Frisina R, Fung C, Kroenke K, Travis LB: Impact of pain and adverse health outcomes on long-term U.S. testicular cancer survivors Journal of the National Cancer Institute
Adra N, Vaughn DJ, Einhorn LH, Hanna NH, Funt SA, Rosales M, Arozullah A, Feldman DR: A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors
Investigational New Drugs
40 (5): 1087-1094,2022.
Grasso C, Popovic M, Isaevska E, Lazzarato F, Fiano V, Zugna D, Pluta J, Weathers B, D'Andrea K, Almstrup K, Anson-Cartwright L, Bishop DT, Chanock SJ, Chen C, Cortessis VK, Dalgaard MD, Daneshmand S, Ferlin A, Foresta C, Frone MN, Gamulin M, Gietema JA, Greene MH, Grotmol T, Hamilton RJ, Haugen TB, Hauser R, Karlsson R, Kiemeney LA, Lessel D, Lista P, Lothe RA, Loveday C, Meijer C, Nead KT, Nsengimana J, Skotheim RI, Turnbull C, Vaughn DJ, Wiklund F, Zheng T, Zitella A, Schwartz SM, McGlynn KA, Kanetsky PA, Nathanson KL, Richiardi L.: Association study between polymorphisms in DNA methylation-related genes and testicular germ cell tumor risk Cancer Epidemiology Biomarkers Prevention
31 (9): 1769-1779,2022.
Roberson D, Jia H, Vaughn D, Miller C, Fogt F, Kovell RC: Effective control of recurrent and metastatic GU SCC by employing a multimodal approach in a patient with a history of radiation and transscrotal surgery for stage I seminoma Urology Case Reports 45 : 102223,2022.
Division of Hematology Oncology Perelman Center for Advanced Medicine10th Floor, South PavilionOffice #10-1143400 Civic Center Blvd
Patient appointments: 800-789-7366